GET DAILY SIGNALSNeuronetics (STIM): Analyst Consensus Points to $6.00 With +270% Upside Potential
Key Takeaways
- The central target of $6.00 is the arithmetic mean of four currently cited analyst price targets, which range from $5.00 to $7.00.
- STIM last traded near $1.62, so reaching $6.00 would require a gain of roughly 270% — an exceptionally large move.
- Analysts view STIM as a "Strong Buy," but some aggregators still carry older targets near $3.00, reflecting a wide spread of opinion.
- Supporting factors include growing treatment-session demand, the Greenbrook TMS clinic integration, and improving margins on the path toward profitability.
- Key risks include persistent losses, high leverage, share dilution, and heavy reliance on the NeuroStar transcranial magnetic stimulation (TMS) platform.
- For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages.
- You can also explore Trending AI Robots to see automated strategies monitoring stocks like this one.
Analyst Price Targets and Consensus View
Neuronetics, Inc. (STIM) is a Malvern, Pennsylvania-based medical technology company whose NeuroStar Advanced Therapy System uses TMS to treat major depressive disorder (MDD). Four currently cited analyst targets — including BTIG at $6.00 and B. Riley Securities at $6.00, both reiterated or raised in early November 2026 — produce an arithmetic mean of $6.00, with a low-to-high range of roughly $5.00 to $7.00.
That range is wider than it first appears. Some data aggregators still list older targets near $3.00 from Piper Sandler and Canaccord Genuity, which is why certain consensus figures appear lower than $6.00. Analysts remain broadly constructive, with a "Strong Buy" or "Moderate Buy" consensus, but the spread between the cautious $3.00-level targets and the more optimistic $6.00-to-$7.00 targets reflects genuine disagreement about how quickly the company can reach sustained profitability. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
As of mid-November 2026, STIM traded near $1.62, down sharply from levels above $3.00 seen earlier in the year and toward the lower end of a 52-week range of $0.80 to $3.44. Reaching $6.00 from $1.62 would require an upside of about 270%, a very large move even for a volatile small-cap. The stock carries a beta near 1.3 and trades with a price-to-sales ratio under 1x, while the business remains unprofitable, with trailing twelve-month revenue near $160 million and a net loss of about $23 million.
The path to the target would likely depend less on a single quarter and more on a multi-step turnaround: sustained session growth, the full integration of the Greenbrook TMS clinic network acquired in late 2024, and a durable shift from losses to positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) and cash flow.
What Could Support a Move Toward the Target
- Growing adoption of TMS as a non-invasive, non-drug treatment for MDD, with the company's NeuroStar platform FDA-cleared for additional indications.
- The Greenbrook acquisition, which added roughly 90-plus U.S. clinics and created a vertically integrated treatment model.
- Improving fundamentals: recent quarters showed revenue growth near 9% year over year, gross margin expansion above 50%, and lower operating expenses.
- Analyst revisions trending higher, with BTIG and B. Riley both maintaining or lifting their $6.00 targets in early November.
What Could Prevent the Target From Being Reached
- Persistent net losses and negative free cash flow, which keep the company dependent on external financing.
- High leverage, with roughly $88 million in debt against about $22 million in cash and a debt-to-equity ratio near 3.9.
- Dilution risk: shares outstanding rose more than 24% year over year as the company used an at-the-market offering program.
- Concentration risk around a single product platform and intense competition in the mental-health treatment market.
Technical Levels and Market Structure
STIM sits below both its 50-day moving average near $2.40 and its 200-day moving average near $1.88, signaling a damaged near-term trend after the sharp November decline. The $3.00-to-$3.44 zone, which marked prior 2026 highs, represents a meaningful resistance level on any recovery. Below, the $0.80 52-week low is a key support level. Short interest is elevated at more than 9% of shares outstanding, a setup that could amplify upside in a rally but also reflects meaningful skepticism.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though individual firms rarely state a precise timing. Investors should watch quarterly earnings and guidance, the trajectory of the NeuroStar-to-session revenue mix, Greenbrook clinic utilization, any further capital raises, and analyst target revisions. Because the required move is so large, a $6.00 outcome would likely need to unfold over multiple reporting periods rather than a single quarter.
Leveraging AI Daily Buy/Sell Signals for Monitoring
In my view, Tickeron's AI Daily Buy/Sell Signals provide a practical way to track names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs, delivering Buy, Sell, or Hold signals based on market conditions, technical behavior, and data-driven analysis. For a volatile stock such as STIM, it helps surface momentum shifts more efficiently than manual review alone, allowing investors to stay informed on key changes without constant monitoring.
Final Assessment
Whether STIM can reach $6.00 hinges on a turnaround that is only partially underway. The target, the arithmetic mean of four current analyst estimates spanning $5.00 to $7.00, implies a roughly 270% gain from a price near $1.62 — an ambitious objective for a company still losing money and carrying high leverage. Supporters point to growing TMS demand, the Greenbrook integration, and improving margins, while skeptics cite persistent cash burn, dilution, and product concentration. The wide spread between cautious near-$3.00 targets and more bullish $6.00-to-$7.00 targets underscores the uncertainty. The next earnings report, guidance, and any further financing activity will be the most important signals of whether such a move becomes more realistic.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
STIM in +31.31% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where STIM advanced for three days, in 227 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STIM's RSI Oscillator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
STIM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STIM as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for STIM turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 34 similar instances when the indicator turned negative. In 31 of the 34 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
STIM moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STIM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for STIM entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.178) is normal, around the industry mean (4.142). P/E Ratio (-5.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.250) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. STIM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STIM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of non-invasive therapies for psychiatric and neurological disorders
Industry MedicalNursingServices
Advertisement